healthcare · stock-sale · committee-conflict

Ways and Means Health Subcommittee Member Mike Kelly Divests Bristol Myers Squibb Stock

The rare trade from the Pennsylvania Republican coincided with a standard portfolio rebalance but highlights ongoing committee conflicts.

2026-06-19 — Mike Kelly · BMY

Key facts

Rep. Mike Kelly (R-Pa.) made a rare divestment in the healthcare sector, selling between $15,001 and $50,000 of Bristol Myers Squibb Co. (BMY) on May 7, 2026. Kelly is an exceptionally infrequent trader, making this first-time transaction in the pharmaceutical giant stand out.

Kelly serves on the House Committee on Ways and Means, specifically sitting on the Subcommittee on Health. The subcommittee has direct legislative jurisdiction over Medicare reimbursement rates, drug pricing frameworks, and Medicare Part D—programs that represent primary federal revenue drivers for major pharmaceutical manufacturers like Bristol Myers Squibb. Kelly also chairs the Ways and Means Subcommittee on Tax.

On the exact same day as the Bristol Myers Squibb transaction, Kelly also sold between $1,001 and $15,000 of Comcast Corp. (CMCSA). This simultaneous activity suggests the pharmaceutical sale may have been part of a broader, routine portfolio rebalancing or cash-raising effort, potentially managed by a professional financial adviser, rather than a targeted trade on a single issuer.

The trade took place one week after Bristol Myers Squibb released its first-quarter earnings results on April 30, 2026. It also occurred one day before the company filed voting results from its annual shareholder meeting. Corporate insiders at the firm, including Executive Vice President Adam Lenkowsky, also had transaction filings processed during this window, though these were restricted to routine derivative conversions and tax-withholding events.

Under the STOCK Act, members of Congress are required to disclose trades within 45 days, and disclosed amounts are reported in ranges. Kelly filed his disclosure on June 11, 2026, 35 days after the transaction. Our analysis scored the trade's overall significance at 34 out of 100, reflecting its alignment with his committee assignments but acknowledging the high likelihood of a routine, adviser-led portfolio adjustment.

For a lawmaker who rarely touches the stock market, any shift in a portfolio that intersects with his legislative pen is bound to draw attention.

Sources

  1. Bristol Myers Squibb 8-K (April 30, 2026) — SEC EDGAR
  2. Bristol Myers Squibb Q1 2026 Press Release Exhibit 99.1 — SEC EDGAR
  3. Adam Lenkowsky Form 4 Filing — SEC EDGAR
  4. Bristol Myers Squibb 8-K (May 8, 2026) — SEC EDGAR

All stories · Mike Kelly · BMY